farnesyl diphosphate synthase

Minodronic acid monohydrate is an farnesyl diphosphate synthase inhibitor that acts as a bone resorption inhibitor.

BPH-1358 (NSC-50460) (NSC-50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor. With IC50s of 1.8 μM and 110 nM, respectively. And it is active against S. aureus in vitro (MIC ~250 ng mL)[1][2].

Alendronate sodium hydrate (MK 217) is a nitrogen-containing bisphosphonate, which is an effective inhibitor of bone resorption. It is utilized for the treatment and prevention of osteoporosis.

BPH-1358 (NSC50460) free base is a potent human undecaprenyl diphosphate synthase (UPPS) and farnesyl diphosphate synthase (FPPS) inhibitor (IC50s: 110 nM and 1.8 μM) and is active against S. aureus in vitro (MIC ~250 ng mL).

The compound binds and blocks farnesyl diphosphate synthase in the HMG-CoA pathway (IC50 = 460 nM for recombinant human FPPS). It causes macrophage apoptosis and inhibits prenylation and sterol biosynthesis in purified osteoclasts.

YM-53601 is a potent squalene synthase (SQS) inhibitor that inhibits adipogenic biosynthesis and lipid secretion in rodents.YM-53601 is a cholesterol-lowering agent that inhibits farnesyl diphosphate farnesyltransferase 1 (FDFT1).YM-53601 exhibits potential antiviral activity and enhances adriamycin-mediated HCC arrest and cell death in vivo. MJN228 is a lipid-based enzyme.

NE21650, a bisphosphonate, inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.

BPH-1358 mesylate (NSC50460 mesylate), a highly effective inhibitor of both human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS), exhibits IC50 values of 1.8 μM and 110 nM, respectively. Additionally, this compound demonstrates potent in vitro activity against S. aureus, with a minimum inhibitory concentration (MIC) approximately 250 ng mL.